Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Intellia Therapeutics Corp a un objectif de cours consensuel de 567,61 $ basé sur les notes de 38 analystes. Le plus haut est de 1 350 $ émis par HSBC le 10 mai 2024<. Le plus bas est de 100 $ émis par Deutsche Bank le 5 août 2024. Les 3 dernières notations d'analystes ont été publiées par New Street Research, Goldman Sachs et Deutsche Bank respectivement le 6 août 2024, le 5 août 2024 et le 5 août 2024. Avec un objectif de cours moyen de 118,33 $ entre New Street Research, Goldman Sachs et Deutsche Bank, il existe une hausse implicite de 0,21 % pour Intellia Therapeutics Corp à partir de ces notations d'analystes les plus récentes.
Sociétés d'analyse émettant des recommandations1
Wells Fargo
JMP Securities
Barclays
RBC Capital
Bernstein
1calculé à partir des notes des analystes
Notes d'analystes pour Intellia Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/28/2025 | — | Wells Fargo | $45 → $17 | Downgrade | Overweight → Equal-Weight | |||
10/28/2025 | — | JMP Securities | $33 → $29 | Maintains | Market Outperform | |||
10/28/2025 | — | Barclays | $26 → $24 | Maintains | Overweight | |||
10/28/2025 | — | RBC Capital | $21 → $14 | Downgrade | Outperform → Sector Perform | |||
10/28/2025 | — | Bernstein | $14 → $14.5 | Downgrade | Outperform → Market Perform | |||
10/27/2025 | — | B of A Securities | $36 → $30 | Maintains | Buy | |||
10/27/2025 | — | HC Wainwright & Co. | $30 → $25 | Maintains | Buy | |||
10/27/2025 | — | Chardan Capital | $60 → $48 | Maintains | Buy | |||
10/06/2025 | — | JMP Securities | → $33 | Upgrade | Market Perform → Market Outperform | |||
09/19/2025 | — | JMP Securities | — | Reiterates | Market Perform → Market Perform | |||
09/19/2025 | — | HC Wainwright & Co. | $25 → $30 | Maintains | Buy | |||
08/13/2025 | — | Guggenheim | $45 → $14 | Maintains | Buy | |||
08/11/2025 | — | Chardan Capital | $68 → $60 | Maintains | Buy | |||
08/08/2025 | — | RBC Capital | $25 → $21 | Maintains | Outperform | |||
08/08/2025 | — | Wells Fargo | $50 → $45 | Maintains | Overweight | |||
08/08/2025 | — | HC Wainwright & Co. | $30 → $25 | Maintains | Buy | |||
06/16/2025 | — | HC Wainwright & Co. | $30 → $30 | Reiterates | Buy → Buy | |||
06/03/2025 | — | Canaccord Genuity | $74 → $54 | Maintains | Buy | |||
05/29/2025 | — | HC Wainwright & Co. | $30 → $30 | Reiterates | Buy → Buy | |||
05/20/2025 | — | HC Wainwright & Co. | $30 → $30 | Reiterates | Buy → Buy | |||
05/19/2025 | — | Wedbush | $10 → $10 | Reiterates | Neutral → Neutral | |||
05/12/2025 | — | Guggenheim | $55 → $45 | Maintains | Buy | |||
05/09/2025 | — | Citigroup | $14 → $10 | Maintains | Neutral | |||
05/09/2025 | — | Chardan Capital | $68 → $68 | Maintains | Buy | |||
04/21/2025 | — | Wolfe Research | → $21 | Upgrade | Peer Perform → Outperform | |||
03/05/2025 | — | HC Wainwright & Co. | → $30 | Initiates | → Buy | |||
03/04/2025 | — | Truist Securities | $90 → $50 | Maintains | Buy | |||
02/28/2025 | — | Barclays | $55 → $26 | Maintains | Overweight | |||
02/28/2025 | — | Citigroup | $12 → $14 | Maintains | Neutral | |||
02/28/2025 | — | Wells Fargo | $60 → $50 | Maintains | Overweight | |||
02/28/2025 | — | Chardan Capital | $91 → $68 | Maintains | Buy | |||
02/28/2025 | — | JP Morgan | $45 → $13 | Downgrade | Overweight → Neutral | |||
01/27/2025 | — | Morgan Stanley | $56 → $11 | Downgrade | Overweight → Equal-Weight | |||
01/14/2025 | — | Goldman Sachs | $19 → $12 | Maintains | Neutral | |||
01/13/2025 | — | Oppenheimer | $60 → $40 | Maintains | Outperform | |||
01/10/2025 | — | Wells Fargo | $70 → $60 | Maintains | Overweight | |||
01/10/2025 | — | BMO Capital | $70 → $50 | Maintains | Outperform | |||
11/19/2024 | — | Canaccord Genuity | $90 → $90 | Maintains | Buy | |||
11/18/2024 | — | Wells Fargo | $80 → $70 | Maintains | Overweight | |||
11/18/2024 | — | Wedbush | $14 → $14 | Reiterates | Neutral → Neutral | |||
11/18/2024 | — | Chardan Capital | $88 → $91 | Maintains | Buy | |||
11/11/2024 | — | Oppenheimer | $70 → $60 | Maintains | Outperform | |||
11/08/2024 | — | Barclays | $76 → $55 | Maintains | Overweight | |||
10/25/2024 | — | Citigroup | $25 → $19 | Maintains | Neutral | |||
10/25/2024 | — | Goldman Sachs | $31 → $20 | Maintains | Neutral | |||
10/25/2024 | — | Baird | $24 → $18 | Maintains | Neutral | |||
10/24/2024 | — | Chardan Capital | $94 → $88 | Maintains | Buy | |||
09/19/2024 | — | RBC Capital | $54 → $54 | Reiterates | Outperform → Outperform | |||
09/17/2024 | — | Jones Trading | → $41 | Initiates | → Buy | |||
09/11/2024 | — | Stifel | $80 → $64 | Maintains | Buy | |||
08/12/2024 | — | JP Morgan | $61 → $55 | Maintains | Overweight | |||
08/09/2024 | — | RBC Capital | $60 → $54 | Maintains | Outperform | |||
06/27/2024 | — | Canaccord Genuity | $73 → $73 | Maintains | Buy | |||
06/24/2024 | — | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
06/24/2024 | — | Truist Securities | $120 → $120 | Maintains | Buy | |||
06/18/2024 | — | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
06/04/2024 | — | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
05/10/2024 | — | Citigroup | $31 → $29 | Maintains | Neutral | |||
05/10/2024 | — | BMO Capital | $62 → $70 | Maintains | Outperform | |||
04/23/2024 | — | Wedbush | $29 → $29 | Reiterates | Neutral → Neutral | |||
02/23/2024 | — | Goldman Sachs | → $32 | Downgrade | Buy → Neutral | |||
02/23/2024 | — | Canaccord Genuity | $72 → $73 | Maintains | Buy | |||
02/15/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/13/2023 | — | Oppenheimer | $80 → $70 | Maintains | Outperform | |||
11/13/2023 | — | Morgan Stanley | $90 → $85 | Maintains | Overweight | |||
11/10/2023 | — | BMO Capital | $64 → $62 | Maintains | Outperform | |||
11/10/2023 | — | RBC Capital | $80 → $70 | Maintains | Outperform | |||
11/10/2023 | — | Goldman Sachs | $157 → $136 | Maintains | Buy | |||
11/10/2023 | — | Raymond James | $78 → $57 | Maintains | Outperform | |||
11/09/2023 | — | Wedbush | $45 → $29 | Maintains | Neutral | |||
09/13/2023 | — | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
08/29/2023 | — | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
08/09/2023 | — | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
08/07/2023 | — | Barclays | $86 → $90 | Maintains | Overweight | |||
08/07/2023 | — | Canaccord Genuity | $66 → $65 | Maintains | Buy | |||
08/07/2023 | — | Chardan Capital | → $107 | Reiterates | Buy → Buy | |||
08/04/2023 | — | Citigroup | $44 → $40 | Maintains | Neutral | |||
08/04/2023 | — | Barclays | $148 → $90 | Maintains | Overweight | |||
06/13/2023 | — | B of A Securities | $89 → $91 | Maintains | Buy | |||
06/13/2023 | — | Chardan Capital | $111 → $107 | Maintains | Buy | |||
06/13/2023 | — | Credit Suisse | → $76 | Reiterates | Outperform → Outperform | |||
05/08/2023 | — | Citigroup | $39 → $44 | Maintains | Neutral | |||
05/08/2023 | — | Oppenheimer | $93 → $90 | Maintains | Outperform | |||
05/08/2023 | — | Morgan Stanley | $83 → $86 | Maintains | Overweight | |||
05/05/2023 | — | BMO Capital | $57 → $64 | Maintains | Outperform | |||
05/05/2023 | — | Raymond James | $94 → $78 | Maintains | Outperform | |||
04/13/2023 | — | Canaccord Genuity | → $66 | Initiates | → Buy | |||
03/31/2023 | — | JP Morgan | $82 → $79 | Maintains | Overweight | |||
03/21/2023 | — | Bernstein | → $54 | Initiates | → Outperform | |||
03/14/2023 | — | BMO Capital | $54 → $57 | Upgrade | Market Perform → Outperform | |||
02/27/2023 | — | Chardan Capital | $129 → $111 | Maintains | Buy | |||
02/24/2023 | — | Credit Suisse | $88 → $76 | Maintains | Outperform | |||
02/24/2023 | — | Oppenheimer | $115 → $93 | Maintains | Outperform | |||
02/24/2023 | — | Baird | $58 → $42 | Maintains | Neutral | |||
02/24/2023 | — | EF Hutton | $123 → $116 | Maintains | Buy | |||
02/24/2023 | — | Raymond James | $124 → $94 | Maintains | Outperform | |||
02/01/2023 | — | Cantor Fitzgerald | → $67 | Initiates | → Overweight | |||
01/24/2023 | — | Citigroup | $48 → $39 | Upgrade | Sell → Neutral | |||
01/23/2023 | — | SVB Leerink | $86 → $84 | Maintains | Outperform | |||
01/19/2023 | — | JMP Securities | — | Downgrade | Market Outperform → Market Perform |
FAQ
Quel est le cours indicatif de l'action Intellia Therapeutics (NTLA) ?
Le dernier objectif de prix pour Intellia Therapeutics (NASDAQ:NTLA) a été rapporté par Wells Fargo le octobre 28, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $17.00 s'attendant à ce que NTLA se rise dans les 12 prochains mois (un possible changement de 27.20% upside). 43 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Intellia Therapeutics (NTLA) ?
La dernière note d'analyste pour Intellia Therapeutics (NASDAQ:NTLA) a été fournie par Wells Fargo, et Intellia Therapeutics réduit leur note equal-weight.
Quand a eu lieu la dernière mise à niveau pour Intellia Therapeutics (NTLA) ?
La dernière amélioration pour Intellia Therapeutics Inc a eu lieu le octobre 6, 2025 lorsque JMP Securities a augmenté leur objectif de prix à $33. JMP Securities avait précédemment a market perform pour Intellia Therapeutics Inc.
Quand a eu lieu la dernière dégradation pour Intellia Therapeutics (NTLA) ?
La dernière réduction pour Intellia Therapeutics Inc a eu lieu le octobre 28, 2025 lorsque Wells Fargo a changé leur objectif de prix de $45 à $17 pour Intellia Therapeutics Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Intellia Therapeutics (NTLA) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Intellia Therapeutics, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Intellia Therapeutics a été déposée le octobre 28, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 28, 2026.
La note d'analyste pour Intellia Therapeutics (NTLA) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Intellia Therapeutics (NTLA) était un réduit avec un objectif de prix de $45.00 à $17.00. Le prix actuel de Intellia Therapeutics (NTLA) est de $13.37, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.